Categories: News

Columbus Chemical Industries, Inc. (CCI) Completes Sale to Employee Stock Ownership Plan (ESOP)

COLUMBUS, Wis., Feb. 10, 2022 /PRNewswire-PRWeb/ — After nearly 44 years in business, Columbus Chemical Industries (CCI) has transitioned to a 100% ESOP (Employee Stock Ownership Plan) owned company. In an announcement made on January 27, 2022, company founder, Richard Sheard outlined how important it was that the CCI employees who helped grow a strong, prosperous company should share in its ownership into the future.

In the announcement meeting, after expressing his gratitude for efforts by the CCI team, but before telling employees that the company was sold to the ESOP, Richard stated along with the other Shareholders he had sold the company. After a pause, he then went on to unveil that the new owners were the employees, to which there was applause and amazement.

Thanking Richard and the shareholders for making such a wonderful decision to benefit the long-term future of CCI and all its associates, President Randall Eppli indicated Richard’s legacy of serving customers and honoring CCI associates will carry-on through an employee-owned company.

About CCI: With facilities in Wisconsin and Arizona and distributor partners reaching global customers, CCI is a specialty chemical company providing custom engineered solutions for the semiconductor, medical device, biotech, laboratory and industrial manufacturing industries. The CCI team is proud of the recognition regularly received for employee safety, outstanding service, environmentally conscious practices and active community involvement.

For more information on CCI’s transition to an ESOP contact Melissa Hoglund at: ESOP@ColumbusChemical.com.

More information on Columbus Chemical Industries can be found on the CCI website at: http://www.columbuschemical.com.

Media Contact

Melanie Matulonis, Marketing Team Leader, ESOP Partners, +1 (920) 750-5799, mmatulonis@esoppartners.com

Twitter, Facebook

 

SOURCE Columbus Chemical Industries, Inc.

Staff

Recent Posts

Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…

23 minutes ago

Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…

24 minutes ago

Adia Nutrition Inc. Recaps Transformative 2025: Explosive Growth, Strategic Focus, and Path to Nasdaq Uplisting

Winter Park, Florida--(Newsfile Corp. - December 29, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a…

27 minutes ago

Changing Healthcare Trajectories With Positive Experiences

DaVita works with others in under-resourced communities to offer individualized health engagements, break down mistrust…

27 minutes ago

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its…

27 minutes ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

Contract Research Organization for the REGAL trial has informed the Company that 72 events have…

28 minutes ago